# US 2010/0168062 A1 · Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168062 A1
- Document ID: US20100168062A1
- Status: Published application
- Kind: A1
- Application number: 12/663,698
- Filed: 2008-06-06
- Published: 2010-07-01
- Earliest claimed: 2007-06-08
- Assignees: Novartis AG
- Inventors: Marc Gerspacher; Pascal Furet; Eric Vangrevelinghe; Carole Pissot Sondermann; Christoph Gaul; Philipp Holzer
- Web page: https://patentgrep.com/patent/US20100168062A1

## CPC

- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 241/42: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to quinoxaline compound of the formula (I): wherein R1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R7; R2 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R8; R3, R4, R5 and R8 are each independently hydrogen or R9; and R7, R8 and R9 are each independently selected from organic and inorganic substituents, their use in therapy of diseases, in particular diseases mediated by the tyrosine kinase activity of Janus kinases, including JAK-2 and JAK-3 kinases.

## Claims

### Claim 1

A compound of formula (I)
wherein
R1 is carbocyclyl or heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R7;
R2 is aryl or heteroaryl, either of which is optionally substituted with 1, 2, 3, 4 or 5 R8;
R3, R4 and R5 are each independently hydrogen or R9;
R6 is hydrogen; and
R7, R8 and R9 are each independently selected from organic and inorganic substituents;
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 2 (depends on 1)

A compound of formula (I) as defined in claim 1, wherein R1 is substituted with at least one R7 and R2 is substituted with at least one R8.

### Claim 3 (depends on 1)

A compound of formula (I) as defined in claim 1, wherein R2 is aryl.

### Claim 4 (depends on 3)

A compound of formula (I) as defined in claim 3, wherein R2 is phenyl.

### Claim 5 (depends on 1)

A compound of formula (I) as defined in claim 1, wherein R1 is heterocyclyl.

### Claim 6 (depends on 5)

A compound of formula (I) as defined in claim 5, wherein R1 is pyridinyl or pyrazolyl.

### Claim 7 (depends on 1)

A compound of formula (I) as defined in claim 1, wherein R3 is H.

### Claim 8 (depends on 1)

A compound of formula (I) as defined in claim 1, wherein the compound is of the formula (II):
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 9 (depends on 8)

A compound of formula (I) as defined in claim 8, wherein the compound is of the formula (IV):
wherein m and n are each independently 1, 2, 3, 4 or 5;
or a pharmaceutically acceptable salt or prodrug thereof.

### Claim 10 (depends on 1)

Use of a compound according to claim 1, or a pharmaceutically acceptable salt or prodrug thereof, for the manufacture of a medicament for the treatment, prevention or delay or progression of a proliferative or immunological disease

### Claim 11 (depends on 10)

Use according to claim 10, wherein the disease is a proliferative disease selected from tumor diseases, leukaemias, polycythemia vera, essential thrombocythemia and myelofibrosis with myeloid metaplasia.

### Claim 12 (depends on 10)

Use according to claim 10, wherein the disease is an immunological disease selected from organ transplant rejection, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, dermatitis, Crohn's disease, type-1 diabetes and complications from type-1 diabetes.

### Claim 13 (depends on 1)

A compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt or prodrug thereof, for therapeutic use.

### Claim 14 (depends on 1)

A pharmaceutical formulation comprising a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutically acceptable carrier or excipient.

### Claim 15 (depends on 14)

A formulation according to claim 14, further comprising one or more antiproliferative, cytostatic or cytotoxic compounds.

### Claim 16 (depends on 1)

A method of treating, preventing or delaying progression of a proliferative or immunological disease in a patient, comprising administering a therapeutically effective amount of a quinoxaline compound according to claim 1,
or a pharmaceutically acceptable salt or prodrug thereof.
